Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CTSH | P09668 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | RAMP3 | O60896 | 2/20 | 0.39 |
| ▸ | CALCR | P30988 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371104 | 1.00 | OPRM1 (0.44) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL30185759 | 0.94 | APLNR (0.48) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL1373233 | 0.90 | APLNR (0.44) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL1373230 | 0.90 | APLNR (0.44) | OPRM1OPRK1CTSLCTSSCTSK | |
| SCHEMBL29451974 | 0.89 | OPRM1 (0.52) | OPRM1OPRK1APLNR | |
| SCHEMBL22300346 | 0.88 | OPRM1 (0.51) | OPRM1OPRK1APLNRGRB2RAMP3 | |
| SCHEMBL30185765 | 0.87 | APLNR (0.47) | OPRM1APLNRGRB2CXCR4RAMP3 | |
| SCHEMBL30419528 | 0.86 | CTSL (0.44) | CTSLCTSSCTSKCTSHAPLNR | |
| SCHEMBL29871917 | 0.85 | OPRM1 (0.46) | OPRM1OPRK1GRB2RAMP3CALCR | |
| SCHEMBL21711187 | 0.85 | F2 (0.47) | OPRM1OPRK1GRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC (CA) | 2016-09-15 | — | — | US | disclosed |
| EP-2794663-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | Angiochem Inc. (CA) | 2014-10-29 | — | — | EP | disclosed |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2011-11-24 | — | — | US | disclosed |
| WO-2010063124-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | ANGIOCHEM INC. (CA) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263235-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRM1 3822/4885OPRK1 3911/4885CTSL 800/4885 |
| US-20110288011-A1 | PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF | VIP, SLC1A5, SLC47A1 | OPRM1 3822/4885OPRK1 3911/4885CTSL 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.